Lilly says labeling for Zyprexa and Symbyax reflects recent data

Share this article:
Eli Lilly & Co. says updated labeling for its atypical antipsychotics Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine HCl) reflects recently completed pooled analyses of clinical trial data in adults and adolescents, information from two non-Eli Lilly studies, and discussions with the FDA.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.